NASDAQ:SGMT • US7867001049
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for SAGIMET BIOSCIENCES INC-A (SGMT).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-11 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2026-02-03 | Guggenheim | Initiate | Buy |
| 2026-02-03 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2026-01-28 | Barclays | Initiate | Equal-Weight |
| 2025-11-14 | Citizens | Maintains | Market Outperform -> Market Outperform |
| 2025-10-22 | Clear Street | Initiate | Buy |
| 2025-10-02 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2025-08-11 | Wedbush | Initiate | Outperform |
| 2025-07-24 | Canaccord Genuity | Initiate | Buy |
| 2025-06-06 | Jones Trading | Maintains | Buy -> Buy |
| 2025-03-13 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-03-11 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-01-27 | Jones Trading | Initiate | Buy |
| 2024-12-06 | Oppenheimer | Initiate | Outperform |
| 2024-11-15 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-11-12 | UBS | Initiate | Buy |
| 2024-10-31 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-10-02 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-08-15 | JMP Securities | Maintains | Market Outperform -> Market Outperform |
| 2024-08-15 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-07-01 | Goldman Sachs | Maintains | Neutral -> Neutral |
| 2024-06-14 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-06-07 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2024-06-07 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-05-24 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 2M | -100.00% | 4.859M | 9.066M 86.58% | 24.429M 169.46% | 117.89M 382.58% | 248.61M 110.88% | 400.17M 60.96% | 477.24M 19.26% | |||||
| EBITDA YoY % growth | N/A | N/A | N/A | -57.282M -72.40% | -61.969M -8.18% | -73.236M -18.18% | -96.9M -32.31% | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -23.719M -108.06% | -31.055M -30.93% | -30.74M 1.01% | -59.273M -77.14% | -62.111M -4.47% | -70.353M -23.67% | -92.191M -31.04% | -99.034M -7.42% | -112.06M -13.15% | -73.182M 34.69% | -29.244M 60.04% | 42.185M 244.25% | 183.11M 334.06% | |
| Operating Margin | N/A | N/A | -1,537.00% | N/A | N/A | N/A | -1,897.33% | -1,092.37% | -458.72% | -62.08% | -11.76% | 10.54% | 38.37% | |
| EPS YoY % growth | N/A | N/A | N/A | -1.60 91.31% | -1.72 -9.79% | -2.00 -27.20% | -2.29 -14.54% | -2.28 0.11% | -2.24 2.01% | -0.97 56.72% | 0.26 127.19% | 1.60 505.88% | 2.47 54.76% |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.36 35.18% | -0.40 -24.03% | -0.45 -13.39% | -0.39 -35.14% | -0.53 -47.24% | -0.42 -6.91% | -0.50 -10.64% | -0.58 -47.83% |
| Revenue Q2Q % growth | ||||||||
| EBITDA Q2Q % growth | -13.872M | -15.81M | -21.114M -53.33% | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -13.715M 30.96% | -14.962M -25.47% | -17.485M -21.98% | -15.792M -1.47% | N/A | N/A | N/A | N/A |
All data in USD
18 analysts have analysed SGMT and the average price target is 25.96 USD. This implies a price increase of 405.13% is expected in the next year compared to the current price of 5.14.
SAGIMET BIOSCIENCES INC-A (SGMT) will report earnings on 2026-05-11, before the market open.
The consensus EPS estimate for the next earnings of SAGIMET BIOSCIENCES INC-A (SGMT) is -0.36 USD and the consensus revenue estimate is 0 USD.
The number of analysts covering SAGIMET BIOSCIENCES INC-A (SGMT) is 18.